Table 4 Characteristics of real-life studies of onabotulinumtoxin A for the treatment of migraine assessing predictors of treatment response
From: Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data
Study | Country | N | % women | Years of age, mean ± SD (range) | % CM | Years from CM onset, mean ± SD (range) | % medication overuse | BT-A dose range (U) | Max follow-up (months) | Definition of response to BT-A | % BT-A responders | Significant predictors of response to BT-A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eross, 2005 [23] | USA | 61 | 90.0 | 46.5 (15–81) | 77 | NR | NR | 25–100 | 4 | ≥50% reduction in headache-related disability | 62.0 | Short duration of migraine |
Jakubowski, 2006 [24] | USA | 27 | 92.6 | 41.9 ± 1.7 | NR | NR | NR | 100 | 12 | > 80% reduction in monthly headache days | 51.9 | Imploding and ocular migraine |
Mathew, 2008 [25] | USA | 71 | 90.1 | (19–69) | 100.0 | NR | NR | 100 | 7 | ≥50% reduction in headache frequency and MIDAS score | 76.1 | Unilateral location, allodynia, pericranial muscle tenderness |
Burstein, 2009 [26] | USA | 82 | 84.1 | 50.9 ± 1.2 (21–75) | 67.0 | NR | NR | NR | NR | > 67% reduction in monthly headache days | 45.1 | Imploding and ocular migraine |
Kim, 2010 [27] | USA | 18 | 94.4 | 50.9 (26–80) | NR | NR | NR | 25–300 | 3 | ≥50% reduction in headache frequency | 77.8 | Imploding and ocular migraine |
Bumb, 2013 [28] | Switzerland | 111 | 85 (responders) 77 (nonresponders) | 47 (responders) 52 (nonresponders) | 66.0 (responders) 62.5 (nonresponders) | NR | NR | 100 | NR | Patients undergoing ≥3 treatments | 57.7 | None |
Lin, 2014 [29] | Taiwan | 94 | 84.0 | 47.6 ± 13.6 (20–85) | 100.0 | 8.1 ± 8.3 (1–40) | 19.1 | 75–155 | 3 | ≥30% reduction in headache frequency | 39.4 | Ocular-type headache |
Lee, 2016 [30] | South Korea | 70 | 85.7 (responders 85.7 (nonresponders) | 48.0 ± 13.6 (responders) 46.9 ± 10. (nonresponders) | 100.0 | Median 10 (IQR 5–17) (responders Median 15 (IQR 10–25) (nonresponders) | 47.6 (responders) 50.0 (nonresponders) | 155 | 1 | ≥50% reduction in headache days, moderate-to-severe headache days, or acute medication intake | 60.0 | Shorter disease duration, higher MCA/ICA index at TCD |
Dominguez, 2017 [31] | Spain | 62 | 97.9 (responders 93.3 (nonresponders) | 51.6 ± 9.1 (responders 39.4 ± 12.0 (nonresponders) | 100.0 | 1.5 ± 1.0 (responders) 1.8 ± 1.3 (nonresponders) | NR | 155 | 6 | ≥50% reduction in frequency of headache | 75.8 | Higher plasma PTX3 and CGRP levels |
Dominguez, 2018 [32] | Spain | 725 | 85.8 | 46.8 ± 12.0 | 100.0 | 1.7 ± 1.6 | 58.2 | NR | 12 | ≥50% reduction in monthly headache days | 79.3 | CM duration, unilateral headache, combined symptomatic treatment, headache-related disability, intensity of headache |
Schiano di Cola, 2019 [33] | Italy | 84 | 72.6 | 48.0 ± 9.7 | 100.0 | 10.1 ± 6.6 | 65.5 | 155–175 | 12 | ≥30% reduction in monthly headache days | 82.6 | Medication overuse, depressive symptoms |